A detailed history of Lazard Asset Management LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 3,031 shares of ARVN stock, worth $57,831. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,031
Previous 3,586 15.48%
Holding current value
$57,831
Previous $95,000 22.11%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$23.66 - $32.73 $13,131 - $18,165
-555 Reduced 15.48%
3,031 $74,000
Q1 2024

May 14, 2024

SELL
$36.38 - $52.31 $39,726 - $57,122
-1,092 Reduced 23.34%
3,586 $148,000
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $66,380 - $198,019
4,678 New
4,678 $192,000
Q2 2022

Aug 09, 2022

BUY
$36.01 - $74.24 $62,765 - $129,400
1,743 Added 202.44%
2,604 $109,000
Q1 2022

May 13, 2022

BUY
$60.27 - $81.57 $51,892 - $70,231
861 New
861 $57,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.